<DOC>
	<DOCNO>NCT01130025</DOCNO>
	<brief_summary>The purpose study assess efficacy safety Innohep® prevent recurrence VTE patient active cancer acute VTE episode .</brief_summary>
	<brief_title>Long-Term Innohep® Treatment Versus Vitamin K Antagonist ( Warfarin ) Treatment Venous Thromboembolism ( VTE ) Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin A</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Retinol palmitate</mesh_term>
	<criteria>Patients diagnosis active cancer . Symptomatic objectively confirm VTE . ≥ 18 year age legal age consent per country specific regulation . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Signed informed consent . Life expectancy &lt; 6 month . Patients basal cell carcinoma nonmelanoma skin cancer . Creatinine clearance ≤ 20 ml/min . Contraindications anticoagulation . Known hypersensitivity investigational product ( Innohep® ) reference product ( warfarin ) . History heparininduced thrombocytopenia ( HIT ) . Prerandomisation therapeutic anticoagulant treatment acute VTE administer 72 hour prior randomisation . Patients unlikely comply protocol . Participation another interventional study . Pregnant breastfeed woman . Women childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>